

10th MILAN CONGRESS ON ANTICANCER INNOVATIVE THERAPY



Milan, 23-24 January 2020

AULA MAGNA GIANNI BONADONNA

Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1 - Milan

Sistema Socio Sanitario



GIOVANNI APOLONE
(Milan, Italy)

MATTEO BELLONE
(Milan, Italy)

SILVIO BICCIATO
(Modena, Italy)

PAOLO BRUZZI
(Genova, Italy)

PIERFRANCO CONTE
(Padua, Italy)

FILIPPO DE BRAUD
(Milan, Italy)

GIANNINO DEL SAL
(Trieste, Italy)

MICHELE DEL VECCHIO
(Milan, Italy)

MASSIMO DI NICOLA
(Milan, Italy)

ALEXANDER EGGERMONT
(Paris, France)

SOLDANO FERRONE
(Boston, USA)

JOHN HISCOTT
(Rome, Italy)

MICHAEL LISANTI
(Salford, UK)

LUCA MAGNANI
(London, UK)

ALBERTO MANTOVANI
(Milan, Italy)

SAVERIO MINUCCI
(Milan, Italy)

STEPHEN PETTITT
(London, UK)

DIRK SCHADENDORF
(Essen, Germany)

PRESENTATION

The “**10th Milan Congress on Anticancer Innovative Therapy**” will collect leading international experts in the field of immunoncology and cancer cell signaling to understand the potential, opportunities and challenges of the immunotherapy and targeted therapies.

The key role of the immune system in cancer has been recognized for a long time.

Our understanding of the co-evolution of cancer and the immune system has significantly improved, with significant results in clinic. Indeed, the increasing knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, allowed us to identify and apply more effective anti-cancer biological and immunological treatments. To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorithms of several different tumor types.

Furthermore, elucidating resistance mechanisms and exploiting cancer vulnerabilities to therapeutics will ultimately improve cancer therapy and patient care.

This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.

Finally, several data supporting the combination of immunotherapies and standard treatments open an intriguing challenge, but also a real opportunity for the future therapeutic approaches.

23 JANUARY 2020

16.00-16.40 Registration

16.40-16.50 Welcome remarks of Scientific Director
G. Apolone (Milan, Italy)

16.50-17.00 Introduction • **M. Di Nicola** (Milan, Italy)

17.00-17.30 Novel targets in anticancer treatment
D. Schadendorf (Essen, Germany)
Presented by **M. Di Nicola** (Milan, Italy)

17.30-18.00 LECTURE OF THE 10TH ANNIVERSARY:
Innate Immunity, Inflammation and Cancer:
double edged swords • **A. Mantovani** (Milan, Italy)
Presented by **M. Del Vecchio** (Milan, Italy)

24 JANUARY 2020

09.00- 09.20 Registration

I SESSION: PRECLINICAL EVIDENCES AND NEW TARGETS

Chairmen: **F. de Braud** (Milan, Italy), **S. Ferrone** (Boston, USA)

- 09.20-09.50 Diving in the dark matter of the breast cancer genome
L. Magnani (London, UK)
- 09.50-10.20 Eradicating Cancer Stem Cells (CSCs) with Anti-Mitochondrial Therapeutics: Pre-clinical Evidence and Clinical Trials
M. Lisanti (Salford, UK)
- 10.20-10.50 Synthetic Lethal Targeting of the DNA Damage Response: PARP inhibitors and beyond • **S. Pettitt** (London, UK)
- 10.50-11.10 General discussion
- 11.10-11.30 *Coffee Break*
- 11.30-12.00 NIBIT Lecture: Novel diagnostic and therapeutic targets in the crosstalk between prostate cancer stem-like cells and the tumor microenvironment • **M. Bellone** (Milan, Italy)

KEYNOTE LECTURE

- 12.00-12.30 p53 at the crossroads of mechano-signalling and metabolic pathways in cancer • **G. Del Sal** (Trieste, Italy)
Presented by **M. Di Nicola** (Milan, Italy)
- 12.30-13.30 *Buffet Lunch*

II SESSION: CLINICAL TRANSLATION

Chairmen: **M. Del Vecchio** (Milan, Italy), **J. Hiscott** (Rome, Italy)

- 13.30-14.00 Novel insights into tumor cell metabolism • **S. Minucci** (Milan, Italy)
- 14.00-14.30 Immunotherapy in Melanoma from advanced to adjuvant to neoadjuvant • **A. Eggermont** (Paris, France)
- 14.30-15.00 New targets: new endpoints? • **P. Bruzzi** (Genova, Italy)
- 15.00-15.30 Integrative bioinformatics in precision oncology
S. Bicciato (Modena, Italy)
- 15.30-16.00 Targeted therapies: present and future • **P. Conte** (Padua, Italy)
- 16.00-16.30 AWARD FOR THE BEST ABSTRACT
- 16.30-16.45 Conclusions • **M. Del Vecchio** (Milan, Italy)
- 16.45-17.00 CME Questionnaire compilation

GENERAL INFORMATIONS

CONGRESS VENUE

Aula Magna Gianni Bonadonna
Fondazione IRCCS
Istituto Nazionale dei Tumori
Via G. Venezian, 1 - MILAN

SCIENTIFIC COMMITTEE

Filippo de Braud - Milan, Italy
Michele Del Vecchio - Milan, Italy
Massimo Di Nicola - Milan, Italy
Gianpietro Dotti - Chapel Hill, USA
Soldano Ferrone - Boston, USA
John Hiscott - Rome, Italy

BEST ABSTRACT AWARD

having as its first author a Researcher
< of 35 years
Send by January 20, 2020
to info@nadirex.com

ORGANIZING SECRETARIAT



Nadirex International Srl
Via Riviera 39 · 27100 Pavia
Tel. +39.0382.525714/35
Fax +39.0382.525736
E-mail: info@nadirex.com
www.nadirex.com

OFFICIAL LANGUAGE

English

CME PROVIDER NR. 265

Nadirex International Srl



CME

The request for CME credits has been submitted to the Italian Ministry of Health.
ID Nr. 265-279270 - CME credits: Nr. 7

- Nr. Of training hours: 7
- Educational goal: Nr. 2
- Guidelines-Protocols-Procedures
- Type of event: Congress / Symposium / Conference / Seminary

The Congress is intended for the following figures:

- Physician

(Ematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine)

- Biologist

- Biomedical laboratory technician

Participants: 100.

In order to obtain CME credits, participants have to:

- Attend 90% of the sessions scheduled in the Scientific Program
- Correctly fill in CME questionnaire (giving the 75% of correct answers)
- Belong to one of the figures for which the congress is intended
- Return the documentation filled-in and signed to the Organizing Secretariat
- Sign the attendance register at the beginning and at the end of the Congress.

The CME certificate will be sent by mail after the Congress to the address given on the personal data form.

REGISTRATION

The registration is free and includes:

- Participation in the conference work
- Congress Kit
- Certificate of Attendance
- CME credits Certificate
- Coffee breaks and lunch as scheduled
- Post event educational material

REGISTRATION INSTRUCTIONS

The Congress provides for a maximum of 100 participants.

Registration online at www.nadirex.com within January 20th, 2020.

The Organizing Secretariat will confirm the registration by email.

REGISTRATION FORM



Fill in using capital letters and send to:
NADIREX INTERNATIONAL s.r.l.

Registration online: www.nadirex.com
within: **January 20th, 2020**

PLEASE COMPLETE THE FOLLOWING DETAILS

CME PROVIDER NR. 265 Nadirex International Srl
ID Nr. 265-279270 - CME credits: Nr. 7

Participants: 100.

The Congress is intended for the following figures:

- Physician (Ematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine)
- Biologist
- Biomedical laboratory technician

PHISYCIAN BIOLOGIST BIOMEDICAL LABORATORY TECHNICIAN

Name

Surname

Profession

Discipline

Specialized

Clinic/Institute

Division/Department

Address

Postal Code Town/City Province

Tel.


Fax

Mobile Tel.

E-mail

I authorise the use of my personal data in accordance with Legislative Decree 196/2003

Date Signature



WITH THE SUPPORT OF:

